寡进展肿瘤SBRT后健康相关生活质量:II期前瞻性试验结果
6个月时全队列平均GHS和QLQ-C30汇总分分别下降7分和5分,均未达MCID;消化道患者下降达MCID,未进展者83%维持或改善GHS。
要点
- SBRT治疗寡进展肿瘤耐受良好,全队列HRQoL下降未达临床重要差异。
- 消化道肿瘤患者GHS下降达MCID,提示临床有意义恶化。
- 进展是6个月GHS更差的独立预测因素,未进展者HRQoL稳定。
核心结论
- SBRT治疗寡进展肿瘤耐受良好,HRQoL下降主要由疾病进展驱动,仅在消化道患者中达临床意义。
- 未进展患者SBRT后HRQoL维持稳定。
研究设计与样本
- 所有寡进展灶接受SBRT,患者继续原有全身治疗。
- 采用EORTC QLQ-C30问卷在基线、放疗期间及SBRT后6周、3个月、6个月评估HRQoL,MCID定义为变化大于10分。
主要发现
- 未进展患者中83%维持或改善GHS,91%维持或改善QLQ-C30评分。
关键数值与推荐
- MCID定义为EORTC QLQ-C30评分变化大于10分。
- 6个月时任何部位进展发生率:泌尿生殖56%、乳腺48%、消化道87%。
临床怎么用
- 对寡进展患者行SBRT时应预期整体HRQoL可耐受,但需关注消化道肿瘤患者的临床有意义生活质量下降。
- 疾病进展是HRQoL恶化的主要驱动因素,未进展者SBRT后HRQoL稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to report changes in patient-reported health-related quality of life (HRQoL) from a phase II trial evaluating stereotactic body radiation therapy (SBRT) for oligoprogressive (OP) tumors. The study hypothesis was that SBRT would not be associated with a deterioration in HRQoL. METHODS AND MATERIALS: This single-arm, phase II prospective study enrolled patients with metastatic genitourinary (GU), breast, or gastrointestinal (GI) cancers with radiographic OP disease in fewer than 5 sites. All OP sites were treated with SBRT while patients continued their existing systemic therapy. HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline, during radiation therapy, and at 6 weeks, 3 months, and 6 months post-SBRT. A minimally clinically important difference (MCID) was defined as a change >10 points . The primary endpoints were the changes in global health status (GHS) and the QLQ-C30 summary score at 6 months. Secondary endpoints included longitudinal GHS assessment over time. RESULTS: Seventy patients were enrolled (32 GU, 23 breast, and 15 GI). At 6 months, any-site progression occurred in 56% of GU, 48% of breast, and 87% of GI patients. For the entire cohort, mean GHS and QLQ-C30 summary scores declined by 7 and 5 points, respectively (P = .02 and P = .03) neither reaching the MCID. Patients with GU cancer had no significant GHS change (P = .99), whereas patients with breast cancer experienced a statistically significant but nonmeaningful decline (P = .01). Patients with GI cancer had a statistically significant decline that reached the MCID, indicating a clinically meaningful deterioration (P = .007). Progression was an independent predictor of worse GHS at 6 months (P = .003). Among patients without progression, 83% maintained or improved GHS and 91% maintained or improved QLQ-C30 scores. CONCLUSIONS: SBRT for OP tumors is well tolerated. HRQoL declines were primarily driven by disease progression and were clinically meaningful in patients with GI. Patients without progression maintained stable HRQoL following SBRT.
引用
- Helou J, Glicksman R, Bezjak A, et al. Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41547376. doi:10.1016/j.ijrobp.2025.12.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。